Drugs in obstetrics / Obstetrics and Gynecology

Lutein 50 mg 30s vaginal tablets

Brands: Polfa (Poland)

$26.40

Quantity

Lutein 50 mg 30s vaginal tablets quantity

Add to cart

Add to wishlist

Sku:

1d76168ef757

Brands:: Polfa (Poland)

Description

The instruction for medical use of medicine of Lutein the Trade name of Lutein the International unlicensed name Progesterone Dosage Form of the Tablet vaginal 50 mg Structure One tablet contains active agent – progesterone of 50 mg, excipients: corn starch, lactoses monohydrate, a gipromelloza, citric acid monohydrate, magnesium stearate the Description of the Tablet of round shape, with a biconvex surface, white color, with the line of a break on one party, Pharmacotherapeutic group with a diameter of 9 mm Sex hormones and modulators of a reproductive system. Progestogens. Pregninum derivatives. Progesterone. ATH G03DA04 code the Pharmacological Pharmacodynamics Progesterone properties in Lyutein’s drug is synthetic received hormone of a yellow body of an ovary. The most important effect of progesterone on genital function is implementation of an ovulation by means of strengthening of proteolysis of a wall of Graafovy bubbles, the secretory changes of endometrium giving the chance of implantation of oospore, braking of overgrowth of the endometrium caused by effect of estrogen, cyclic changes in muscles of uterine tubes, a neck of the uterus and vagina. Reduces excitability and contractility of muscles of a uterus and uterine tubes. Has no androgenic activity. Has the blocking effect on secretion of hypothalamic release factors of LG and FSG, education by a hypophysis of gonadotropic hormones oppresses and brakes an ovulation. The pharmacokinetics Metabolism After intravaginalny use of 100 mg of progesterone, hormone reaches the maximum concentration in blood plasma about 6 – 7 hours later from the moment of introduction, and this concentration averages 10.9 +/-4.2 ng/ml. Removal Elimination half-life in an elimination phase makes about 13 h of blood plasma of the progesterone entered intravaginalno. Distribution After vaginal introduction progesterone is transported directly in uterus endometrium. Penetration of progesterone from a vagina in a uterus can be carried out on the mechanism of direct diffusion in fabric of endometrium, transportation through a neck, transportation with a venous and lymphatic blood-groove or way of the facilitated counterflow diffusion from absorbent and venous vessels to the arterial system of a uterus. Indications endometriosis support of a lyuteinovy phase at artificial fertilization the infertility connected with lyuteinovy insufficiency the usual and menacing abortions against the background of deficiency of progesterone insufficiency of a lyuteinovy phase during the premenopausal period hormonal replacement therapy at the women after a menopause with the kept uterus receiving hormonal replacement therapy for the purpose of protection of endometrium. A route of administration and doses the Dosage of progesterone has to be established always individually depending on indications and therapeutic effect. at insufficiency of a lyuteinovy phase enter into the premenopausal period intravaginalno 25-50 mg of progesterone 2 times a day in the second phase of a menstrual cycle (natural or reproduced) for 10-12 days at hormonal replacement therapy in combination with estrogen enter 25-50 mg of progesterone intravaginalno 2 times a day, at faltering therapy from the 15th to the 25th day of a cycle or at continuous therapy daily in progesteronovy test at a secondary amenorrhea progesterone is entered intravaginalno in a dose on 50 mg by 2 times a day for 5-7 days (bleeding haswithin 7-10 days from the moment of the treatment termination by progesterone) at treatment of dysfunctional bleedings from patrimonial ways enter 50 mg of progesterone intravaginalno 2 times a day for 5-7 days. Treatment it is necessary to continue within consecutive 2-3 months in a dose on 25-50 mg 2 times a day intravaginalno from the 15th to the 25th day of a cycle in uterus endometriosis progesterone enter intravaginalno 50-100 mg 2 times a day in the form of continuous therapy for 6 months at the menacing abortions, a usual miscarriage, the anovulatory and induced cycles enter intravaginalno 50-150 mg of progesterone 2 times a day in case of a usual miscarriage the administration of progesterone should be begun during a cycle in which pregnancy is planned. Treatment should be continued continuously approximately up to 18-20 weeks of pregnancy. in programs of artificial fertilization enter 300 mg of progesterone 2 times a day intravaginalno. Treatment is continued continuously till 77th day after movement of an embryo. The end of therapy has to happen by gradual decrease in the accepted drug dose. Side effects Perhaps: drowsiness, disturbances of concentration and attention, sensation of fear, depressions, headaches and dizziness allergic reactions (rash, an itching), yellowness of skin and scleras intermenstrual bleeding, reduction of a menstrual cycle, hypersensitivity, pain and swelling of mammary glands, disturbances from external genitals such as dryness, burning, genital itching, the profound vaginitis, vaginal mycosis of a disorder of vision and speech peripheral hypostases, hypostases under eyes of pain in gastrocnemius muscles, feeling of numbness change of body weight paroxysmal short wind, thorax pains, cough with blood discharge nausea, vomiting, an abdominal distension, an abdominal pain, a constipation, Contraindication diarrhea tendency to fibrinferments acute phlebitis or a thrombembolia bleeding of not clear etiology from a genital tract incomplete abortion a porphyria children’s and teenage age up to 18 years the established or suspected malignant new growths of mammary glands and genitals the lactation period, the II-III trimester of pregnancy hypersensitivity to drug components, including to peanut butter, soy hereditary intolerance of fructose, deficiency of LAPP enzyme – lactase, glucose galactose malabsorption. With care it is necessary to use drug in diseases of a cardiovascular system, arterial hypertension, chronic kidney disease, diabetes, bronchial asthma, epilepsy, migraine, a depression, a giperlipoproteinemiya. Medicinal interactions At combined use of drug are strengthened by effect of diuretics, hypotensive medicines, immunodepressants, anticoagulants. Reduces lactogenic effect of oxytocin. The special instructions Progesterone at intravaginalny introduction gets directly into the blood circulatory system, passing metabolism in a liver. In this regard, patients with disturbances of work of a liver have no need for change of a dose of the progesterone accepted in the vaginal way. Before an initiation of treatment it is necessary to perform gynecologic examination and palpatorny inspection of chest glands. Drug cannot be used for the purpose of contraception. Patients with a depression have to be under special control as progesterone can strengthen disease symptoms. The period of pregnancy and a lactation Progesterone can safely be used in the first trimester of pregnancy. Does not render the masculinizing, virilizing, kortikoidny and anabolic effects. There are no clinical data on use of Progesterone in the second and third trimester of pregnancy. Breastfeeding is restriction to drug use. The feature of influence on ability to run the vehicle or potentially dangerous mechanisms the Progesterone accepted vaginalno does not affect ability of control of vehicles, service of moving mechanisms and on the speed of psychomotor reactions. Overdose Symptoms: drowsiness, dizziness, depression. Treatment: reduction of a dose or drug withdrawal, after reduction of a dose of drug these symptoms completely independently disappear. The form of release and packing On 15 tablets place in blister strip packaging from a white opaque polyvinylchloride/polyvinyldichloride (PVH/PVDH) film and aluminum foil. On 2 planimetric packs together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature not over 25 of 0C to Store out of children’s reach! 2 years not to use a period of storage after an expiration date. Prescription status According to the prescription the Applicant of Adamed Limited Liability Company Pienkov 149, 09-152, Czosnow, Poland Pharmaceutical Works Polfa in Pabianice Joint Stock Company 5, marsz.J.Pilsudskiego str., 95-200 Pabianice Producer, Poland the Owner of the registration certificate of Adamed Limited Liability Company Pienkov 149, 09-152, Czosnow, Poland

Additional information